Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Transplant ; 21(8)2017 Dec.
Article in English | MEDLINE | ID: mdl-29034612

ABSTRACT

MLVI has been used to assess adherence. To determine the MLVI in children <12 years of age at transplantation and to identify demographic correlates and consequences for the graft. This is a retrospective study of 50 outpatients (4.0 ± 3.5 years), at least 13-month post-liver transplantation. The outcomes evaluated were MLVI, ALT > 60 IU/L, ACR, death, and graft loss. We analyzed demographic and socioeconomic characteristics, indication for transplantation, and type of donor. Student's t test and the chi-square test were used. Statistical significance was set at P ≤ .05. Seventy-two percent were infants or preschoolers, 62% biliary atresia. Seventy-four percent of the mothers had middle-school education, and 54% of the families had an income ≤3632.4 US$/y. Twenty-two (44%) patients had a MLVI ≥ 2 SD; this was more prevalent in families with higher incomes (P = .045). ALT levels > 60 IU/L were more common in MLVI ≥ 2 SD group (P = .035). ACR episodes were similar between groups (P = 1.000). No patient died or lost the graft. MLVI ≥ 2 SD may be an indicator of the risk of medication non-adherence.


Subject(s)
Immunosuppressive Agents/blood , Liver Transplantation , Medication Adherence , Tacrolimus/blood , Age Factors , Child , Child, Preschool , Female , Follow-Up Studies , Graft Rejection/diagnosis , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents/pharmacokinetics , Immunosuppressive Agents/therapeutic use , Infant , Male , Outcome Assessment, Health Care , Retrospective Studies , Risk Assessment , Risk Factors , Tacrolimus/pharmacokinetics , Tacrolimus/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL